Evolus (NASDAQ:EOLS) Upgraded at Wall Street Zen

Posted by Brenda Bartman on Aug 11th, 2026

Wall Street Zen upgraded shares of Evolus (NASDAQ:EOLS – Free Report) from a hold rating to a buy rating in a research report released on Saturday morning.

EOLS has been the subject of a number of other research reports. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.50.

Check Out Our Latest Stock Report on EOLS

Evolus Price Performance

Shares of Evolus stock opened at $7.57 on Friday. The stock has a market cap of $500.00 million, a PE ratio of -14.56 and a beta of 1.35. The firm has a fifty day moving average price of $6.52 and a 200 day moving average price of $5.56. Evolus has a 1 year low of $3.86 and a 1 year high of $7.95.

Institutional Trading of Evolus

A number of hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after buying an additional 2,837 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Evolus during the 4th quarter worth about $34,000. Wexford Capital LP purchased a new stake in shares of Evolus during the 3rd quarter worth about $37,000. Tower Research Capital LLC TRC grew its position in shares of Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after acquiring an additional 5,691 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Evolus during the 3rd quarter valued at about $48,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

About Evolus

(Get Free Report)

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.